Lab site
Linkedin
Research Interests
Breast Cancer, Cancer Genomics and Genetics, Tumor evolution, Resistance to treatment, Tumor and gut microbiome in cancer, Tumor microenvironment, MRI of breast cancer.
Education
2011, Postdoctoral training - Computational Biology - Weizmann Institute of Science
2007, Ph.D., Weizmann Institute of Science
M.Sc., Weizmann Institute of Science
B.Sc – Biology, Hebrew University, Jerusalem
Affiliations
2012, Lab of Breast Cancer Translational Research, Cancer Research Center, Sheba Medical Center, Israel
Honors and Awards
2018, ELROV fund - Sheba Innovation Center Award
2018, The Nehemia Rubin Excellence in Biomedical Research – The TELEM Program, supported by the Aaron Gutwirth Fund
2016, EACR - European Association for Cancer Research - poster prize
2015, Cancer Biology Research Center, TAU – Outstanding scientific work
2014, Israeli society for Cancer Research – ISCR best abstract award
2012, IMPAKT breast cancer conference – Brussels, Belgium, best abstract.
2008, Dean Fellowship, Department of computer science, Weizmann Institute of Science
2007, Suzan G. Komen for the Cure Award, AACR
2003, 2004, 2006, Travel stipends, International Society for Magnetic Resonance in Medicine
2003, Avon Foundation Award, AACR
2003, Katzir Scholarship for PhD travel stipend, Weizmann Institute of Science
2002, AstraZeneca Scholar-in-Training Award, AACR
Research grants
2025 - 2026 Israel Cancer Association, Elucidating the role of Stromal Fibroblasts in remodeling MRI Background Parenchymal Enhancement and the underlying effect on Breast Carcinogenesis.
2023 - 2024 Sheba-Bar-Ilan joint grans, Exploring tumor-bacteria interplay in breast cancer by spatial transcriptomics.
2023 - 2023 Sheba 2nd chance, Exploring the human breast cancer intra-tumor microbiome and its clinical significance.
2021 - 2022 Israel Cancer Association, Exploring the clinical significance of the human breast cancer intra-tumor microbiome.
2019 - 2021 Sheba Research fund, Mapping personalized resistance to chemotherapy in breast cancer to predict response.
2019 - 2020 Israel Cancer Association Subtype switch between primary and recurrent breast cancer: the underlying molecular mechanism and therapeutic implications.
2018 - 2023 Sheba, The Nehemia Rubin Excellence in Biomedical Research – The TELEM Program, supported by the Aaron Gutwirth Fund.
2018 - 2019 Israel Cancer Research Fund (ICRF), The role of Intestinal Microbiota in Breast Cancer Progression and Therapy.
2018 Sheba Innovation Center award, Estimation of Peritumoral Interstitial Fluid Flow Velocity.
2016 - 2017 AusiMed, Deciphering the Molecular Mechanisms Underlying Treatment Response & Impact on Outcome in BRCA Mutation Carriers with Triple Negative Breast Cancer.
2015 - 2016 Israel Cancer Research Fund (ICRF), Patterns of Molecular Evolution through the Course of Disease in Recurrent Breast Cancer.
2014 - 2017 Ministry of Science, Israel, A proteogenomic analysis of the response to chemotherapy in breast cancer.
2013 - 2014 Israel Cancer Association, Tumor Evolution Throughout the Neoadjuvant Chemotherapy Timeline in Recurrent Breast Cancer: Profiling Expression Patterns and Genetic Signatures.
Publications
Here is a link to the publications of Dr. Dadiani.
